Form 4: Castle Biosciences COO Kristen Oelschlager Sells Shares Under 10b5-1 Plan

Kristen Oelschlager, Chief Operating Officer of Castle Biosciences, sold 2,793 shares of common stock at a weighted-average price of $21.224 per share on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 1, 2024, Kristen Oelschlager, the Chief Operating Officer of Castle Biosciences, sold 2,793 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on March 15, 2024.
• The shares were sold at prices ranging from $20.890 to $21.705, with a weighted-average sale price of $21.224.
• Following the transaction, Oelschlager directly owns 148,618 shares of Castle Biosciences common stock, which includes 1,109 shares acquired on February 29, 2024, under the Issuer's employee stock purchase plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-existing 10b5-1 plan, which is a common and legal practice.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sale was pre-planned and not based on any specific non-public information.

Stakeholder Impact

• The sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates